Resistance to cisplatin-based chemotherapy is responsible for therapeutic failure of many common human cancers including cancer of head and neck (HNC). Mechanisms underlying cisplatin resistance remain unclear. In this study, we identified neurofilament light polypeptide significantly increased sensitivity to the drug. Further, NEFL physically associated with tuberous sclerosis 1(TSC1), a known inhibitor of the mTOR pathway, and NEFL downregulation led to functional activation of mTOR pathway and consequentially conferred cisplatin resistance. This is the first study to demonstrate a role for NEFL in HNC chemoresistance. Our findings suggest that NEFL methylation is a novel mechanism for HNC chemoresistance and may represent a candidate biomarker predictive of chemotherapeutic response and survival in HNC patients.
Introduction
Although platinum-based chemotherapeutic agents are widely used to treat human malignancies, including head and neck cancer (HNC) (1), intrinsic and acquired resistance of cancer cells to cisplatin accounts for the majority of chemotherapeutic failure in HNC (2) .
Resistance to cisplatin, reported in 15-30% of newly diagnosed and more than 70% of relapsed patients, is an important contributing cause of the more than 12,000 deaths from HNC reported each year in the United States (3) . Alternative therapeutic strategies and predictive biomarkers for cisplatin-resistant HNC are currently lacking.
Mechanisms underlying the development of resistance to platinum drugs are not fully understood (4) . Extracellular and intracellular changes that promote drug metabolism, decreased cellular drug accumulation, altered expression of key molecules in the apoptotic pathway, and increased repair of DNA adducts have been reported to contribute to drug resistance (4) . In HNC, alterations of key molecules mediating cisplatin-induced apoptosis have been implicated in resistance (5) , and mutated or over-expressed p53 and the Bcl-2 protein family, key players in regulating apoptotic pathways, were associated with HNC resistance to cisplatin-based chemotherapy (6) . In addition, altered metabolism in reactive oxygen species (ROS), an essential molecule for cisplatin-induced cell killing, was also observed in HNC (7) . We have demonstrated that amplification and overexpression of glutathione S-transferase, a molecule important for preventing intracellular ROS accumulation, contributes to cisplatin resistance in HNC (8) (9) .
Altered DNA methylation is a hallmark of human cancer and has been shown to contribute to drug resistant disease (10) . Inactivation of tumor suppressor genes by promoter CpG island hypermethylation contributes to tumor initiation and progression, and methylated DNA is a potential source of cancer-specific biomarkers for clinical assessment (11) . Studies using DNA methylation inhibitors (e.g., 5-aza-2-deoxycytidine or 5-aza-dC) to restore DNA damage recognition, repair and apoptosis pathways and thus sensitivity to cisplatin-based chemotherapy further support the important role of DNA methylation in cancer (12) (13) . Although epigenetic alterations in chemoresistant tumors have been reported in ovarian, lung, colon and testicular cancers (10, (14) (15) , aberrant DNA methylation in HNC chemoresistance have only been reported in in vitro cell line models (16) .
To better understand the epigenetic mechanisms underlying cisplatin resistance in HNC and identify novel hypermethylated genes as therapeutic targets and potential HNC biomarkers, we performed genome-wide DNA methylation profiling of isogenic, cisplatin sensitive and resistant HNC cell lines, using an approach that combines gene expression microarray and pharmacologic unmasking (5-aza-2′-deoxycytidine treatment of cancer cells) (17) . This technique has been widely used in methylation screening for different types of cancers (16) (17) .
Among the identified candidates, neurofilament light peptide (NEFL) was selected for analysis, due to its chromosome location of 8p21, a genetic locus previously reported to be frequently deleted in several common cancers, including HNC (18-20). The NEFL gene encodes the light subunit of neurofilaments, which are essential for maintaining neuronal integrity and may play an essential role in intracellular transport to axons and dendrites (21) . In this study, we further examined NEFL methylation and expression in a panel of HNC cell lines and patient tumors with recorded responses to cisplatin-based chemotherapy. We also investigated the functional role and potential mechanisms of NEFL in HNC cisplatin response. Taken together, our results implicate that promoter hypermethylation mediated silencing of NEFL is a novel mechanism for HNC chemoresistance, and methylated NEFL may represent a candidate biomarker predictive of chemotherapeutic response and survival for HNC patients. 
Materials and Methods
Cell lines: A total of 15 HNSCC cell lines, including two isogenic cisplatin sensitive/resistant lines (HN17B/HN17Bcp, SCC25/SCC25cp) were used in this study (Table 1) including treatment histories and survival follow-up, were collected from Georgetown University Lombardi Cancer Center. The patients from this cohort were selected based on availability of adequate tissues. After the initial biopsy, all patients were treated with cisplatin-based chemotherapy for organ preservation or unresectable disease. Determination of chemotherapy responses and patient survival in this cohort has been described previously (24) .
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Clinicopathological features of all patients are described in Table 2 . Sample and data collection was approved by local institutional IRBs.
Real-time RT-PCR: mRNA levels of NEFL transcripts in HNC cell lines were quantitatively assessed by real-time reverse transcriptional PCR. For cDNA synthesis, 2 µg RNA was used for reverse transcription (First-Strand cDNA Synthesis kit; Invitrogen, Carlsbad, CA).
Twenty microliters of cDNA reaction mixture were further diluted to 100 µl and then 3 µl out of 100 µl cDNA for each sample were mixed with Syber Green Master mixture (Roche Diagnostics, Indianapolis, IN) and quantitatively amplified by real-time PCR in a LightCycler 480 instrument using a protocol suggested by manufacturer (Roche Diagnostics). Primers for amplification of NEFL transcript were: Forward: 5'-GAAGAGGAGGCAGCTGGAAGA; and Reverse: 5'-AAGGAAATGGGGGTTCAATC. Quantitative amplification of GAPDH cDNA was performed using the same protocol and used as normalization control. Relative expression levels of NEFL transcript in cell lines were calculated using the previously published formula: 2 -(Ct of NEFL -Ct of GAPDH) (25) 5-Aza-2′-deoxycytidine treatment and reverse transcriptional PCR: HNC cell lines (PCI13, SCC25cp, PCI51 and O28) were treated with 10 μmol/L 5-aza-2′-deoxycytidine (5-AzadC) for 3 days with replacement of the drug and medium every 24 hours. RNA of cell lines was purified using Trizol reagent following the instruction from the manufacturer (Invitrogen, Carlsbad, CA). cDNA synthesis was performed as described above and 3 µl of the diluted cDNA for each sample were amplified by PCR using a protocol described in our previous study(17). Primers for amplification of NEFL transcript were the same as for real-time PCR Amplification of GAPDH cDNA was used as normalization control. PCR products (10 µl) were resolved in 1% agarose gel and visualized by ethidium bromide staining. , as described previously (27) . To determine the optimal cut-off of relative methylation level for discriminating methylated and unmethylated samples, we performed qMSP analysis on serial mixtures of in vitro methylated DNA and methylationnegative lymphocyte DNA. We found that a relative methylation level of value 1.5 was able to detect 25% of methylated DNA copies in 75% of methylation-negative DNA background, and therefore should be sufficiently sensitive to determine the methylation status of primary tumors containing both cancer cells some normal tissues. NEFL expression construct and siRNA: Fulllength NEFL coding sequences was PCR-amplified and cloned into a Topo TA pcDNA3.1 expression vector with an N-terminal HA tag (Invitrogen, Carlsbad, CA). DNA sequencing was used to verify the constructs, and expression efficiency was determined by western blot analysis using HA tag monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA). NEFL siRNA and scrambled control were purchased from Sigma-Aldrich (St. Louis, MO). Figure 1A and Table 1 ), and expression of NEFL in Hacat was high.
Expression status of NEFL was correlated with cisplatin sensitivity. As shown in Figure   1A and Table 1 
NEFL expression, the CpGs assessed were mostly completely unmethylated ( Figure 1A and 1C) .
Based on the patterns of methylated CpGs identified from plasmid cloning and bisulfite DNA sequencing, an MSP assay was designed to detect NEFL promoter methylation in the other HNC cell lines. As shown in Figure 1D , no methylation was detected in an immortalized Hacat cell, and 7/14 of the HNC cell lines analyzed by MSP were positive for NEFL methylation. 
NEFL inhibits mTOR pathway activity by physically interacting with an mTOR suppressor TSC1.
To further investigate the mechanism underlying NEFL-mediated cisplatin resistance, we examined potential pathways modulated by NEFL. NEFL is a critical component of the cytoskeleton, interacting with multiple protein targets essential for cell plasticity, proliferation, migration, apoptosis and molecule transporters (32) (33) . Among these, we further investigated the TSC1 tumor suppressor (Tuberous sclerosis complex 1). TSC1 has been shown to function as a molecular inhibitor of the mTOR oncogenic pathway, reported to be frequently constitutively activated in cisplatin-resistant cancers (28) . NEFL has been shown to bind TSC1 and stabilize the TSC1/2 complex(33). Therefore, we hypothesized that inactivation of NEFL, leading to abnormal activation of mTOR pathway, confers cisplatin resistance.
To test this hypothesis, we examined the status of the mTOR pathway and the effects of altered NEFL expression on mTOR activity in HNC cell lines with and without NEFL silencing. in esophageal cancers (36) . Third, NEFL has been shown to interact with a number of functional molecular targets found in several critical cancer-associated pathways. These NEFL-interacting targets include tuberous sclerosis 1(TSC1)(33), a potent inhibitor of mTOR pathway, and glutamate receptor, ionotropic, N-methyl D-aspartate 1(Grin1) (37), a newly identified TSG in human esophageal carcinoma (26) . Take together, these studies strongly suggest that NEFL, and an intact neurofilament structure, may play a critical role in suppressing cancer initiation and/or progression.
In the current study, we demonstrate that down-regulation of NEFL expression is seen in about 50% of HNC cell lines and correlates with NEFL hypermethylation ( Figure. 1 ). In addition, NEFL CpG island promoter methylation was detected in 49% of HNC primary tumors (Table 2) , but was absent in matched normal oral mucosa tissues ( Figure 1D ). Our study provides the first direct evidence that NEFL is epigenetically silenced in a human cancer and supports the possibility that NEFL may be the putative TSG candidate located at chromosome 8p21, which may have important implications for a broad range of common cancers with frequent 8p21 deletions, including prostate, breast, bladder, lung and liver cancers(18, 30).
Drug resistance is a major limitation for the clinical application of cisplatin and its analogues in HNC chemotherapy, and contributes significantly to morbidity and mortality from HNC (38) . Despite intensive efforts for several decades, the mechanism(s) underlying resistance to cisplatin in HNC patients remains unclear(39). Previous studies have shown that p53 mutations, leading to inactivation of p53 protein and defects of apoptotic responses to chemotherapeutic agents, are strongly associated with cisplatin resistance in HNC (40) . In addition, we have reported a strong association between chromosome 11q13 amplification, resulting in over-expression of glutathione S-transferase pi, which detoxifies cisplatin-induced 
reactive oxygen species, and decreased chemotherapy responses in HNC patients (8) . In this study, we demonstrate that NEFL is silenced by DNA methylation in cisplatin-resistant but not in cisplatin-sensitive HNC cell lines, and our functional studies further demonstrate a requirement for NEFL in cisplatin-induced growth inhibitory responses. Clinically, NEFL methylation was strongly associated patient responses to cisplatin-based chemotherapy. This is the first report to identify down-regulation of NEFL expression by promoter methylation as a novel and important mechanism for HNC chemoresistance.
Predictive and prognostic markers for chemotherapy responses and patient outcomes are highly valuable for guiding therapeutic strategies and improving survival of cancer patients (41) .
Lack of such biomarkers for clinical use has had a substantial influence on the successful management of HNC patients, as HNC morbidity has remained essentially unchanged for several decades (42) .We and others, using immunohistochemical analysis have identified protein biomarkers significantly correlated with chemotherapy responses and HNC patient prognosis (43) . In this study, HNC patients with positive NEFL promoter methylation were nearly three times more likely to be resistant to cisplatin-based chemotherapy than those without NEFL methylation, regardless of other clinical parameters of the patients (Table 2) . NEFL methylation also predicted reduced overall and disease-free survival for HNC patients who received cisplatinbased chemotherapy (Figure 2 ). These findings suggest that NEFL methylation is a candidate independent predictive marker for response to cisplatin-based chemotherapy and that methylated NEFL may predict a more malignant clinical phenotype in HNC patients. We recognize that a limitation of the current study is the small number of patients and that our analysis is not able to Mammalian target of rapamycin (mTOR) is a key downstream protein kinase of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway and has reported to play a central role in controlling cancer cell growth (44) . AKT and mTOR function as "switch" proteins to modulate metabolism, the cell cycle and apoptosis in cancer cells (45) (46) . Constitutive activation of mTOR has been found in common human malignancies, including HNC (44) and has been shown to associate with resistance to several chemotherapeutic agents, including cisplatin (28) . In cultured cortical neurons, NEFL was found to physically bind to the putative tumor suppressor TSC1(33), a molecular inhibitor of mTOR activity. We conducted a series of functional studies to demonstrate that NEFL is required for suppression of mTOR activity in HNC cells.
Furthermore, downregulation of NEFL leads to mTOR activation, confering cisplatin resistance.
We further show that NEFL physically associates with TSC1 in NEFL-expressing PCI13 cells and modulates mTOR activity. Altered mTOR pathway activation also associate with NEFLnegative HNC. These findings provide convincing evidence that activation of mTOR pathway, a consequence of NEFL downregulation by promoter hypermethylation, is one of the mechanisms underlying cisplatin resistance in HNC. However, we recognize that inhibition of mTOR activity by RAD001 alone was not able to restore cisplatin sensitivity in all cell lines with NEFL methylation (e.g., PCI51), suggesting that other mechanisms may be involved in NEFLassociated responses to cisplatin. NEFL has been found to interact with a number of target proteins that participate in various important cellular processes. Among these, glutamate receptor, ionotropic, N-methyl D-aspartate 1 (NMDAR1), a subunit of NMDAR, has recently been shown to be a novel TSG in esophageal carcinoma (26) 
